JPMorgan Chase & Co. Has $83.04 Million Position in Balchem Co. (NASDAQ:BCPC)

JPMorgan Chase & Co. boosted its position in shares of Balchem Co. (NASDAQ:BCPC - Free Report) by 11.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 509,490 shares of the basic materials company's stock after purchasing an additional 50,504 shares during the period. JPMorgan Chase & Co. owned about 1.57% of Balchem worth $83,044,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BCPC. Westside Investment Management Inc. acquired a new stake in shares of Balchem in the third quarter valued at $27,000. R Squared Ltd bought a new stake in Balchem during the 4th quarter worth about $29,000. Wilmington Savings Fund Society FSB acquired a new stake in Balchem in the 3rd quarter valued at about $35,000. Venturi Wealth Management LLC acquired a new position in shares of Balchem during the fourth quarter worth approximately $95,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of Balchem by 230.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 645 shares of the basic materials company's stock valued at $106,000 after purchasing an additional 450 shares during the last quarter. 87.91% of the stock is currently owned by institutional investors and hedge funds.

Balchem Stock Down 2.4 %

Balchem stock traded down $3.63 during mid-day trading on Tuesday, reaching $150.50. The company's stock had a trading volume of 281,738 shares, compared to its average volume of 125,751. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.16 and a current ratio of 1.99. Balchem Co. has a 12 month low of $137.69 and a 12 month high of $186.03. The business's 50 day simple moving average is $164.93 and its 200 day simple moving average is $168.50. The company has a market capitalization of $4.90 billion, a price-to-earnings ratio of 38.30, a price-to-earnings-growth ratio of 4.41 and a beta of 0.75.

Remove Ads

Balchem (NASDAQ:BCPC - Get Free Report) last released its earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.11 by ($0.08). Balchem had a net margin of 13.47% and a return on equity of 11.37%. The firm had revenue of $240.00 million during the quarter, compared to the consensus estimate of $239.96 million. As a group, research analysts anticipate that Balchem Co. will post 4.64 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. HC Wainwright reissued a "buy" rating and set a $190.00 price objective on shares of Balchem in a report on Monday, February 24th. Sidoti raised shares of Balchem to a "hold" rating in a research note on Tuesday, February 25th. Finally, StockNews.com cut shares of Balchem from a "buy" rating to a "hold" rating in a research note on Tuesday, February 25th.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.